메뉴 건너뛰기




Volumn 49, Issue 6, 2013, Pages 399-410

White paper: An outlook on U.S. biosimilar competition

Author keywords

Biologics price competition and innovation act; Biosimilar user fee act; Biosimilars; Patient protection and affordable care act

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; ECULIZUMAB; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIVIZUMAB; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB; USTEKINUMAB;

EID: 84880031596     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.6.2012938     Document Type: Article
Times cited : (7)

References (16)
  • 1
    • 84880018619 scopus 로고    scopus 로고
    • First U.S. State biosimilars bill becomes law
    • March 25
    • Taylor, L. First U.S. state biosimilars bill becomes law. Pharma Times Online, March 25, 2013.
    • (2013) Pharma Times Online
    • Taylor, L.1
  • 3
    • 84880018466 scopus 로고    scopus 로고
    • Biotech firms, billions at risk, lobby states to limit generics
    • January 28
    • Pollock, A. Biotech firms, billions at risk, lobby states to limit generics. New York Times, January 28, 2013.
    • (2013) New York Times
    • Pollock, A.1
  • 5
    • 84880009861 scopus 로고    scopus 로고
    • Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America, June 25
    • Radcliffe, S., Wheadon, D.E. Letter to Margaret Hamburg, MD. Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America, June 25, 2012.
    • (2012) Letter to Margaret Hamburg, MD
    • Radcliffe, S.1    Wheadon, D.E.2
  • 7
    • 84880018515 scopus 로고    scopus 로고
    • It's all about the name: What is the imperative of adopting a unique names for biologic and biosimilar therapeutics?
    • November 28
    • Dolinar, R. It's all about the name: what is the imperative of adopting a unique names for biologic and biosimilar therapeutics? Food and Drug Policy Forum 2012, 2(22). November 28, 2012.
    • (2012) Food and Drug Policy Forum 2012 , vol.2 , Issue.22
    • Dolinar, R.1
  • 9
    • 84879997545 scopus 로고    scopus 로고
    • Web site
    • Biosimilar development. Sandoz Biopharmaceuticals Web site. http://www.sandoz-biosimilars.com/biosimilars/development.shtml.
    • Biosimilar Development


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.